# data[].attributes.headline
It induces Vitamin D3 production.It is shown that CF induced a 19 % increase in endogenous levels of calcitriol, the active form of vitamin D3 (1,25- dihydroxyvitamin D).Reyes-Izquierdo T, Nemzer B, Gonzalez AE, Zhou Q, Argumedo R, Shu C, Pietrzkowski Z (2012) Short-term intake of calcium fructoborate improves WOMAC and McGill scores and beneficially modulates biomarkers associated with knee osteoarthritis: a pilot clinical double-blinded placebo-controlled study. Am J Biomed Sci 4:111–122. doi:10.5099/aj120200111

# data[].attributes.subject
It induces Vitamin D3 production.It is shown that CF induced a 19 % increase in endogenous levels of calcitriol, the active form of vitamin D3 (1,25- dihydroxyvitamin D).Reyes-Izquierdo T, Nemzer B, Gonzalez AE, Zhou Q, Argumedo R, Shu C, Pietrzkowski Z (2012) Short-term intake of calcium fructoborate improves WOMAC and McGill scores and beneficially modulates biomarkers associated with knee osteoarthritis: a pilot clinical double-blinded placebo-controlled study. Am J Biomed Sci 4:111–122. doi:10.5099/aj120200111

# data[].attributes.headline
FruiteX-B® is not genotoxic or mutagenic and it contains 2.5% boron and consumption of the anticipated human dose of 216 mg/day results in an intake of 5.4 mg boron/day, which is within the range of reported safe upper limits of 6-20 mg/day for boron.                         Hathcock, J., 2014. Boron. In: MacKay, D., Wong, A., Nguyen, H. (Eds.), Vitamin and Mineral Safety 3rd Edition. Council for Re-sponsible Nutrition (CRN), Washington, DC, pp. 124e127. www.crn.org (accessed 01.09.15.).Marone, P., Heimbach, J., Nemzer, B. and Hunter, J. (2016). Subchronic and genetic safety evaluation of a calcium fructoborate in rats. Food and Chemical Toxicology, 95, pp.75-88.

# data[].attributes.subject
FruiteX-B® is not genotoxic or mutagenic and it contains 2.5% boron and consumption of the anticipated human dose of 216 mg/day results in an intake of 5.4 mg boron/day, which is within the range of reported safe upper limits of 6-20 mg/day for boron.                         Hathcock, J., 2014. Boron. In: MacKay, D., Wong, A., Nguyen, H. (Eds.), Vitamin and Mineral Safety 3rd Edition. Council for Re-sponsible Nutrition (CRN), Washington, DC, pp. 124e127. www.crn.org (accessed 01.09.15.).Marone, P., Heimbach, J., Nemzer, B. and Hunter, J. (2016). Subchronic and genetic safety evaluation of a calcium fructoborate in rats. Food and Chemical Toxicology, 95, pp.75-88.

# data[].attributes.headline
CLINICAL STUDY RELATED TO INFLAMMATION and PRO-ATHEROGENIC MARKERS                                                           A double-blind, placebo-controlled clinical study has been designed to determine the effects of CF on levels of CRP, total cholesterol (TC), LDL cholesterol, triglycerides, interleukin- 1β (IL-1β), interleukin-6 (IL-6), and MCP-1 (monocyte chemoattractant protein-1). The objective of this study was to investigate whether CF alters blood levels of lipids, homocysteine, CRP, IL-1β, IL-6, and MCP-1 in generally healthy middle-aged subjects in order to evaluate the poten-tial use of CF as a dietary supplement to support cardiovascular health. Our results suggest that use of CF at a daily dose as low as 112 mg for 30 days may significantly reduce levels of the pro inflammatory and pro-atherogenic markers TC, LDL cholesterol, triglycerides, CRP, and homocysteine, while increasing the levels of HDL cholesterol, which is considered a pro-tective lipid. Furthermore, supplemental use of CF at a dose of 112 mg per day (3 mg B and 5.26 mg Ca) appears to have a statistically significant inhibitory effect on pro-inflammatory cytokines such as IL-1β, IL-6, and MCP-1. In humans, plasma levels of MCP-1 correlate with the severity of cardiovascularconditions. Several researchers have postulated that blocking or reducing the expression of MCP-1 might be beneficial in preventing the development of unhealthy heart conditions.Our results suggest that use of CFB at a daily dose as low as 112 mg for 30 days may signifi-cantly reduce levels of the proinflammatory and proatherogenic markers TC, LDL, triglycerides, CRP, and homocysteine while increasing the levels of HDL, which is considered a protective lipid. Furthermore, supplemental use of CFB at a dose of 112 mg per day appears to have a statistically significant inhibitory effect on proinflammatory cytokines such as IL-1β, IL-6, and MCP-1.REF: Rogoveanu OC, Mogoşanu GD, Bejenaru C, Bejenaru LE, Croitoru O, Neamţu J, Pietrzkowski Z, Reyes-Izquierdo T, BiţăA, Scorei ID, Scorei RI (2015) Effects of calcium fructoborate on levels of C-reactive protein, total cholesterol, low-density lipoprotein,triglycerides, IL-1β, IL-6, and MCP-1: a double-blind, placebo-controlled clinical study. Biol Trace Elem Res 163:124–131.

# data[].attributes.subject
CLINICAL STUDY RELATED TO INFLAMMATION and PRO-ATHEROGENIC MARKERS                                                           A double-blind, placebo-controlled clinical study has been designed to determine the effects of CF on levels of CRP, total cholesterol (TC), LDL cholesterol, triglycerides, interleukin- 1β (IL-1β), interleukin-6 (IL-6), and MCP-1 (monocyte chemoattractant protein-1). The objective of this study was to investigate whether CF alters blood levels of lipids, homocysteine, CRP, IL-1β, IL-6, and MCP-1 in generally healthy middle-aged subjects in order to evaluate the poten-tial use of CF as a dietary supplement to support cardiovascular health. Our results suggest that use of CF at a daily dose as low as 112 mg for 30 days may significantly reduce levels of the pro inflammatory and pro-atherogenic markers TC, LDL cholesterol, triglycerides, CRP, and homocysteine, while increasing the levels of HDL cholesterol, which is considered a pro-tective lipid. Furthermore, supplemental use of CF at a dose of 112 mg per day (3 mg B and 5.26 mg Ca) appears to have a statistically significant inhibitory effect on pro-inflammatory cytokines such as IL-1β, IL-6, and MCP-1. In humans, plasma levels of MCP-1 correlate with the severity of cardiovascularconditions. Several researchers have postulated that blocking or reducing the expression of MCP-1 might be beneficial in preventing the development of unhealthy heart conditions.Our results suggest that use of CFB at a daily dose as low as 112 mg for 30 days may signifi-cantly reduce levels of the proinflammatory and proatherogenic markers TC, LDL, triglycerides, CRP, and homocysteine while increasing the levels of HDL, which is considered a protective lipid. Furthermore, supplemental use of CFB at a dose of 112 mg per day appears to have a statistically significant inhibitory effect on proinflammatory cytokines such as IL-1β, IL-6, and MCP-1.REF: Rogoveanu OC, Mogoşanu GD, Bejenaru C, Bejenaru LE, Croitoru O, Neamţu J, Pietrzkowski Z, Reyes-Izquierdo T, BiţăA, Scorei ID, Scorei RI (2015) Effects of calcium fructoborate on levels of C-reactive protein, total cholesterol, low-density lipoprotein,triglycerides, IL-1β, IL-6, and MCP-1: a double-blind, placebo-controlled clinical study. Biol Trace Elem Res 163:124–131.

# data[].attributes.headline
CLINICAL STUDY RELATED TO OSTEOARTHRITIS                                                  A double-blind, placebo-controlled study evaluated the effect of CF on systemic inflamma-tion and dyslipidemia markers for middle-aged people with primary osteoarthritis, 15 sub-jects per group. CF supplementation tested over a 14-day period at a serving of 57 mg per day (1.5 mg B and 2.85 mg Ca). CRP was reduced by 60.25 % versus baseline, pre supplemen-tation value. The CF group also experienced a reduction in elevated levels of erythrocyte sed-imentation rate (−10.25 %) and fibrinogen (−13.73 %), other common measures of inflamma-tion. This study also provides important information regarding the possible molecular mech-anisms of an anti-inflammatory compound with an identical natural origin in the nutrition of osteoarthritis (OA) demonstrated that CF has potential efficacy in terms of reducing pain and improving the physical ability of OA patients. Summing up, the presented data have im-portant implications for new strategy development for preventing OA and dyslipidemia asso-ciated with fructoborate supplementation.Ref: Scorei R, Mitrut P, Petrisor I, Scorei I (2011) A double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructobo-rate on systemic inflammation and dyslipidemia markers for middle-aged people with primary osteoarthritis. Biol Trace Elem Res 144:253–263. doi:10.1007/s12011-011-9083-0

# data[].attributes.subject
CLINICAL STUDY RELATED TO OSTEOARTHRITIS                                                  A double-blind, placebo-controlled study evaluated the effect of CF on systemic inflamma-tion and dyslipidemia markers for middle-aged people with primary osteoarthritis, 15 sub-jects per group. CF supplementation tested over a 14-day period at a serving of 57 mg per day (1.5 mg B and 2.85 mg Ca). CRP was reduced by 60.25 % versus baseline, pre supplemen-tation value. The CF group also experienced a reduction in elevated levels of erythrocyte sed-imentation rate (−10.25 %) and fibrinogen (−13.73 %), other common measures of inflamma-tion. This study also provides important information regarding the possible molecular mech-anisms of an anti-inflammatory compound with an identical natural origin in the nutrition of osteoarthritis (OA) demonstrated that CF has potential efficacy in terms of reducing pain and improving the physical ability of OA patients. Summing up, the presented data have im-portant implications for new strategy development for preventing OA and dyslipidemia asso-ciated with fructoborate supplementation.Ref: Scorei R, Mitrut P, Petrisor I, Scorei I (2011) A double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructobo-rate on systemic inflammation and dyslipidemia markers for middle-aged people with primary osteoarthritis. Biol Trace Elem Res 144:253–263. doi:10.1007/s12011-011-9083-0

# data[].attributes.headline
CLINICAL STUDY RELATED TO CRP LEVELS AND VITAMIN D3                           A double-blind, placebo-controlled study was performed on healthy volunteers, 10 subjects per group. CF supplementation tested over a 14-day period at a serving of 108 mg (2.91 mg B and 5.4 mg Ca) twice per day. CRP was reduced by 37 % versus baseline, pre-supplementation value. CF also induced a 19 % increase in endogenous levels of calcitriol, the active form of vitamin D3 (1,25- dihydroxyvitamin D). Blood level of CRP in 7 out of 10 subjects was found reduced up to 37 % compared to day 1 baseline levels. Interestingly, the study also showed that blood level of endogenous vitamin D3 was increased more than 19% compared to base-line.Ref: Reyes-Izquierdo T, Nemzer B, Gonzalez AE, Zhou Q, Argumedo R, Shu C, Pietrzkowski Z (2012) Short-term intake of calcium fructoborate improves WOMAC and McGill scores and beneficially modulates biomarkers as-sociated with knee osteoarthritis: a pilot clinical double-blinded placebo-controlled study. Am J Biomed Sci 4:111–122. doi:10.5099/aj120200111

# data[].attributes.subject
CLINICAL STUDY RELATED TO CRP LEVELS AND VITAMIN D3                           A double-blind, placebo-controlled study was performed on healthy volunteers, 10 subjects per group. CF supplementation tested over a 14-day period at a serving of 108 mg (2.91 mg B and 5.4 mg Ca) twice per day. CRP was reduced by 37 % versus baseline, pre-supplementation value. CF also induced a 19 % increase in endogenous levels of calcitriol, the active form of vitamin D3 (1,25- dihydroxyvitamin D). Blood level of CRP in 7 out of 10 subjects was found reduced up to 37 % compared to day 1 baseline levels. Interestingly, the study also showed that blood level of endogenous vitamin D3 was increased more than 19% compared to base-line.Ref: Reyes-Izquierdo T, Nemzer B, Gonzalez AE, Zhou Q, Argumedo R, Shu C, Pietrzkowski Z (2012) Short-term intake of calcium fructoborate improves WOMAC and McGill scores and beneficially modulates biomarkers as-sociated with knee osteoarthritis: a pilot clinical double-blinded placebo-controlled study. Am J Biomed Sci 4:111–122. doi:10.5099/aj120200111

# data[].attributes.headline
SAFETY EVALUATION                                                           The safety of FruiteX-B® Brand Calcium Fructoborate was examined in a subchronic dietary study of oral toxicity and two in vitro genotoxicity studies in mammalian and bacterial sys-tems. The mutagenicity studies in S. typhimurium and E. coli strains and the in vitro micronu-cleus test using Chinese hamster cells demonstrated that the test article is not mutagenic or genotoxic under these conditions. FruiteX-B® Brand Calcium Fructoborate contains 2.5% boron and consumption of the antici-pated human dose of 216 mg/day results in an intake of 5.4 mg boron/day, which is within the range of reported safe upper limits of 6-20 mg/day for boron (Hathcock, 2014).Ref: Marone, P., Heimbach, J., Nemzer, B. and Hunter, J. (2016). Subchronic and genetic safety evaluation of a calcium fructoborate in rats. Food and Chemical Toxicology, 95, pp.75-88.

# data[].attributes.subject
SAFETY EVALUATION                                                           The safety of FruiteX-B® Brand Calcium Fructoborate was examined in a subchronic dietary study of oral toxicity and two in vitro genotoxicity studies in mammalian and bacterial sys-tems. The mutagenicity studies in S. typhimurium and E. coli strains and the in vitro micronu-cleus test using Chinese hamster cells demonstrated that the test article is not mutagenic or genotoxic under these conditions. FruiteX-B® Brand Calcium Fructoborate contains 2.5% boron and consumption of the antici-pated human dose of 216 mg/day results in an intake of 5.4 mg boron/day, which is within the range of reported safe upper limits of 6-20 mg/day for boron (Hathcock, 2014).Ref: Marone, P., Heimbach, J., Nemzer, B. and Hunter, J. (2016). Subchronic and genetic safety evaluation of a calcium fructoborate in rats. Food and Chemical Toxicology, 95, pp.75-88.

# data[].attributes.headline
Calcium fructoborate (FruiteX-B), a natural sugar-borate ester found in fresh fruits and vegetables, is a source of soluble boron. It is commercially produced by a patented process that was first described by Miljkovic et al. (US Patent #5,962,049)

# data[].attributes.subject
Calcium fructoborate (FruiteX-B), a natural sugar-borate ester found in fresh fruits and vegetables, is a source of soluble boron. It is commercially produced by a patented process that was first described by Miljkovic et al. (US Patent #5,962,049)